AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
BoomRay Pharmaceuticals Enters Exclusive Global License Agreement with Novartis for Preclinical Radioligand Asset.
Sep 22, 2026•about 2 hours ago
Contract Type
agreement
BiotechnologyHealth CareMedicalTherapeutics
Description
BoomRay Pharmaceuticals has entered an exclusive global license agreement with Novartis for a preclinical radioligand therapy asset. This agreement allows Novartis to leverage BoomRay's development expertise in the radioligand therapy space.
Company Information
Company
BoomRay Pharmaceuticals
About
BoomRay Pharmaceuticals is focused on the discovery and development of innovative cancer therapies. The company specializes in radioligand therapy, aiming to improve treatment outcomes for cancer patients. With a commitment to advancing its therapeutic programs, BoomRay collaborates with industry leaders to enhance its capabilities.
Predictive Intelligence
Strategic
ML-powered predictions for BoomRay Pharmaceuticals's next move